Abstract
Background: Kasabach-Merritt syndrome (KMS) is a consumptive coagulopathy associated with the presence of a large vascular lesion. It is often a frustrating condition to treat and it carries a high mortality rate. There are currently no known treatment guidelines. Kasabach-Merritt syndrome is associated with kaposiform hemangioendothelioma (KHE) and tufted angioma (TA); these lesions, when associated with KMS, are locally invasive, aggressive vascular tumors. Treatment options include supportive care, local therapies, and drug and surgical management. In most recent case reports, a multimodal approach to therapy is taken. Objective and Conclusion: The objective of this article is to provide a comprehensive review of KMS and give an up-to-date summary of treatment options. The clinical presentation, laboratory findings, vascular pathology, and pathophysiology will also be discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 335-339 |
| Number of pages | 5 |
| Journal | Journal of Cutaneous Medicine and Surgery |
| Volume | 6 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 2002 |
Fingerprint
Dive into the research topics of 'Kasabach-Merritt syndrome'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS